News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


LCT starts DIABECELL® Phase IIb trial

Living Cell Technologies Limited
Company Announcement

LCT starts DIABECELL® Phase IIb trial in Argentina

22 November 2012: Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) has begun patient recruitment in Argentina for a Phase IIb trial of DIABECELL®.

The trial is designed to demonstrate the clinical benefits of DIABECELL in unstable type 1 diabetes. Twenty patients will receive two implants of 10,000 IEQ/kg (islet equivalents per kilogram of body weight), with the second implant occurring 12 weeks after the first. This is the dose which was shown to be most clinically effective in reducing HbA1c, insulin dose and unaware hypoglycaemic events in the interim analysis of the Phase I/IIa trial in Argentina, announced today.

The principal investigator of the Phase IIb trial is Dr Adrián Abalovich of Hospital Eva Perón in San Martín, Buenos Aires.

“We are using an ‘adaptive trial design’ for our pivotal studies and so the data generated in this 20 patient trial will likely form the foundation data for our registration package,” said Dr Andrea Grant, Chief Executive, LCT. “We remain on track to meet our goal of completing clinical trials of DIABECELL by 2015 and having a product commercially available by 2016.”

DIABECELL is a breakthrough treatment for people with unstable type 1 diabetes and is the first islet transplant treatment that does not require ongoing administration of debilitating immunosuppression drugs. DIABECELL is owned by the joint venture company Diatranz Otsuka Limited, in which LCT and Otsuka Pharmaceutical Factory both have a 50% interest.


– Ends –

For further information: www.lctglobal.com

About DIABECELL
Diabetes is usually treated with insulin replacement. A serious and potentially fatal complication associated with intensive insulin replacement therapy is unaware hypoglycaemia. Episodes of unaware hypoglycaemia occur when, without associated symptoms or warning, blood glucose levels drop suddenly. Some patients require significant time and resources from specialist healthcare professionals and have a poor prognosis: lower quality of life, more micro vascular and pregnancy complications and shortened life expectancy.
Treatment with DIABECELL® involves transplanting pig pancreatic islet cells into a patient’s abdomen to boost insulin production and help regulate blood glucose levels. The cells are encapsulated with IMMUPEL™ to prevent the immune system rejecting them as foreign. This proprietary technology ensures the cells can deliver their beneficial effects without the patient requiring immunosuppressant drugs.
DIABECELL is owned by the joint venture company Diatranz Otsuka Limited, in which LCT and Otsuka Pharmaceutical Factory both have a 50% interest.
For a summary of DIABECELL’s clinical trial programme please see the DIABECELL clinical trial update on LCT’s website www.lctglobal.com or DIABECELL clinical trial update.

About Living Cell Technologies
Living Cell Technologies (LCT) leads the world in developing cell-based therapeutics to treat diseases with high unmet clinical need. Its proprietary cell encapsulation technology IMMUPEL™ allows for cell transplantation without the need for immunosuppressant drugs.
LCT’s lead therapeutic candidate DIABECELL® is indicated for the treatment of patients with type 1 diabetes, especially those suffering from life threatening episodes of unaware hypoglycaemia (low blood sugar), a dangerous and potentially fatal diabetes complication. DIABECELL is currently in Phase II clinical trials in both New Zealand and in Argentina.
In 2011, LCT formed a partnership with Otsuka Pharmaceutical Factory Inc (OPF) in which the joint venture Diatranz Otsuka Limited (NZ) was established. Valued at A$50m on formation, LCT vested the DIABECELL product and associated IP into the JV, while OPF vested A$25m to fund the final phase of development of DIABECELL through to market approval. Both LCT and OPF are 50:50 shareholders in the current and future value generated by DIABECELL and the associated IP.
LCT has also developed NTCELL®, a choroid plexus cell product, to treat neurodegenerative diseases such as Parkinson’s disease and stroke. NTCELL’s trial results indicate potential for protecting, repairing and possibly regenerating brain tissue which would otherwise die.
LCT is incorporated in Australia. Research and development, operations and manufacturing facilities are based in New Zealand.

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Photos: Inside The Christchurch Arts Centre Rebuild

Lady Pippa Blake visited Christchurch Arts Centre chief executive André Lovatt, a 2015 recipient of the Blake Leader Awards. The award celebrated Lovatt’s leadership in New Zealand and hisand dedication to the restoration of the Arts Centre. More>>

Running Them Up The Flagpole: Web Tool Lets Public Determine New Zealand Flag

A School of Design master’s student is challenging the flag selection process by devising a web tool that allows the public to feed their views back in a way, he says, the current government process does not. More>>

ALSO:

Survey: ‘The Arts Make My Life Better’: New Zealanders

New Zealanders are creative people who believe being involved in the arts makes their lives better and their communities stronger. Nine out of ten adult New Zealanders (88%) agree the arts are good for them and eight out of ten (82%) agree that the arts help to improve New Zealand society. More>>

ALSO:

Wellington.Scoop: Reprieve For Te Papa Press

Following its review of the role of Te Papa Press, Te Papa has committed to continue publishing books during the museum’s redevelopment, Chief Executive Rick Ellis announced yesterday. More>>

Law Society: Sir Peter Williams QC, 1934 - 2015

“Sir Peter was an exceptional advocate. He had the ability to put the defence case for his clients with powerful oratory. His passion shone through in everything he did and said.” Mr Moore says Sir Peter’s lifelong commitment to prison reform was instrumental in ensuring prison conditions and the rights of prisoners were brought to public attention. More>>

ALSO:

CTU: Peter Conway – Family Statement

Peter committed his whole working life to improving the lives of working people, both in unions and, more recently, as the Economist and Secretary of the Council of Trade Unions. He was previously Chair of Oxfam New Zealand and was on the Board of NZ Trade and Enterprise. More>>

ALSO:

Hundertwasser Art Museum: Whangarei Says Yes

Provisional results confirm Whangarei voted Option B in a landslide result for the Hundertwasser and Wairau Maori Art Centre project. 13,726 voted for the Hundertwasser project in a FPP binding referendum that had higher voter turnout than the last local body election. More>>

ALSO:

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news